http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2636112-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
filingDate | 2007-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9a7fd2923c9bdbac3f262bd97957c0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd53ce2c4146d033830f604a531158d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d361c8cd448909c6953bdb08cd51e78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d765946d0f18275765aa09d565a13c4 |
publicationDate | 2007-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2636112-A1 |
titleOfInvention | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives useful for the treatment of alzheimer's disease via gaba receptors |
abstract | The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives of formula (I): wherein R1 is hydrogen, halogen, hydroxy, lower alkyl, benzyloxy or -O-(CH2)-(CO)-5 or 6 membered heteroaryl optionally substituted by aryl or by lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkynyl, amino, -NHC(O)-Ra or -(CO)-Ra; R3 is hydrogen, halogen, cyano, lower alkyl, lower alkynyl, amino, -NHC(O)-Ra, -(CO)-Ra, -5 or 6-membered heterocycloalkyl in 1-position, optionally substituted 10 by =O or is a -5 or 6-membered heteroaryl in 1-position; R4 is hydrogen or -5 or 6-membered heteroaryl; R5 is lower alkyl or cycloalkyl; Ra is lower alkoxy or NR'R'', wherein R' and R'' are each independently hydrogen, lower alkyl optionally substituted by hydroxy, lower alkynyl, -(CH2)n-cycloalkyl, 15 -(CH2)n-5 or 6-membered heterocycloalkyl or -(CH2)n-5 or 6-membered heteroaryl; n is 0 to 3; as well as pharmaceutically acceptable acid addition salts thereof. It has been found that this class of compounds show high affinity and selectivity for GABA A .alpha.5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. |
priorityDate | 2006-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 303.